Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0242379 (
lung cancer
)
71,905
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The aim of the research was to examine age-specific features of incidence of cancer of the esophagus, lung, stomach, breast, cervix and thyroid gland in the Aral Sea area in Kazakhstan. A retrospective study of 11 years (1999-2009) was conducted using descriptive and analytical methods with calculated age incidence rates. The average age of patients with esophageal cancer and
lung cancer
had a tendency for increase with "aging", while in other cases "juvenation" was noted. The peak incidence of malignant tumors in general, and in the studied forms of cancer was found at 70 years of age or older, except for breast cancer and cervical cancer, where the peak incidence was found at 60-69 years. Trends in age-varied incidence rates had different tendencies in particular organ sites.
Asian
Pac
J Cancer Prev 2011
PMID:Age characteristics of incidences of prevalent cancers in the Aral Sea area of Kazakhstan. 2229 73
Lung cancer
is the most common cancer worldwide but data from Tunisia are limited. The aim of this research was to describe the epidemiology, pathology and clinical features of
lung cancer
in Central Tunisia. All
lung cancer
cases diagnosed during a 15-year period were analyzed based on the data of the Cancer Registry of the Center of Tunisia. Five-year age-specific rates, world age-standardized rates (ASR), and annual percent change were calculated using annual data on population size and the estimated age structure. A total of 1,882 incident cases of
lung cancer
were registered (1,782 males, 100 females). The median age at diagnosis was 64 years for males and 61 years for females, with ASRs of 35.2 per 100,000 among males and 1.5 among females. Over time, there were significant decreasing trends by -6.5% (95% CI: -12.9%; -0.2%) for females and a stable incidence for males at an annual rate of +0.2% (95% CI: -1.6%; +1.8%). The predominant histological type was squamous cell carcinoma in males (36.9%) and adenocarcinoma in females (52%). During 2003-2007, adenocarcinoma became the most frequent (33.7%) followed by squamous cell carcinoma (30.3%) in males. The majority of tumor cases were diagnosed at advanced stages (79.9%). In conclusion,
lung cancer
has remained the most common cancer diagnosed at advanced stages among Tunisian men. Our findings justify the need to plan and develop effective programs aiming at the control and prevention of the spread of
lung cancer
in Tunisia.
Asian
Pac
J Cancer Prev 2011
PMID:Lung cancer in central Tunisia: epidemiology and clinicopathological features. 2229 75
Lung cancer
is a prevalent cancer with a high death rate. Underlying mechanisms have been found to be highly correlated with epigenetics, especially with DNA methylation. With methylation array and other regulation data, we constructed a TF-gene regulation network and a TF-pathway network. Through those networks, we identified
lung cancer
related genes that were found by previous studies, and supposed a number of new examples. Our work demonstrated the new potential methylation for
lung cancer
.
Asian
Pac
J Cancer Prev 2011
PMID:Transcriptome-wide network analysis of squamous lung cancer reveals potential methylation genes. 2229 82
It is well-known that tobacco smoke is a definite causative agent important for human health. Epidemiological research has proven that smoking is a cause of various serious and fatal diseases. However, never-smokers comprise a high proportion of non-small-cell
lung cancer
(NSCLC) patients. To determine whether
lung cancer
patients in never smokers have different genetic mutations from their counterparts in smokers, we comprehensively searched the Cochrane Library, Medline and EMbase from 1966 to Jun 2010 for the following terms: ("non- smoker" or "never-smoker") and ("lung cancer") and ("gene") limited to English and clinical trials. Although a significant fraction of lung cancers in never smokers may also be attributable to tobacco, many such cancers arise in the absence of detectable tobacco exposure, and may follow a very different molecular pathway of malignant formation, including EGFR gene mutation, P53 mutation and metabolic gene CYP1AIIle462Val polymorphism. These genes will help doctors to separate never-smoker
lung cancer
from smokers, and may present promising targets for therapy of never-smoker lung cancers. Future efforts should focus on further delineation of underlying biologic differences, identifying potential non-tobacco-related risk factors, and refining treatment strategies for different groups of
lung cancer
patients.
Asian
Pac
J Cancer Prev 2011
PMID:Never smokers with lung cancer: analysis of genetic variants. 2232 Sep 97
MicroRNAs (miRNAs) play critical roles in many different cellular processes, including metabolism, apoptosis, differentiation, and development. In this study, miR-663 was shown to be highly expressed in patients with
lung cancer
. Furthermore, miR-663 contributed to
lung cancer
cell proliferation of by regulating TGFB1, P53, Bax, and Fas directly or indirectly. Our results demonstrated that miR-663 plays an important role in the biology of
lung cancer
and may be useful in developing therapies targeting genes.
Asian
Pac
J Cancer Prev 2011
PMID:MicroRNA-663 targets TGFB1 and regulates lung cancer proliferation. 2239 47
Lung cancer
is the primary cause of cancer death in the world. Although it is well established that tobacco smoke causes
lung cancer
, not all smokers develop
lung cancer
. Manganese superoxide dismutase (MnSOD), a major determinant of antioxidants in matrix mitochondria, plays a pivotal role in eliminating anion superoxide free radical generated from the tobacco smoke. The aim of this study was to analyze the enzyme activity of MnSOD in blood of
lung cancer
patients with a smoking history in relationship to oxidative stress. Samples were taken from leukocyte cells of 20
lung cancer
patients in Persahabatan Hospital Jakarta. Control groups included 50 healthy smokers and 50 non smokers, all aged over 40 years. The MnSOD activity determined biochemically based on the inhibition of xanthin oxidase, of
lung cancer
patients was lower than the control group's (p<0.001). Plasma MDA levels, determined by reaction with thiobarbituric acid (TBA), were not significantly different (p=0.479), whereas plasma carbonyl levels were elevated (p=0.003). Free radical production in
lung cancer
patients thus appeared high. Smoker controls also tended to exhibit lower MnSOD and higher carbonyl radicals than their non-smoking counterparts. Continue cigarette smoke exposure may increase production of ROS and bring about a reduction of MnSOD, which could play a role in
lung cancer
development.
Asian
Pac
J Cancer Prev 2011
PMID:Low activity of manganese superoxide dismutase (MnSOD) in blood of lung cancer patients with smoking history: relationship to oxidative stress. 2239 88
Studies have shown that immune cells play a key role in
lung cancer
development. Five SNPs (rs1494555, rs7737000, rs20541, rs1057972 and rs2857261) are associated with
lung cancer
risk among Caucasians and/or African-Americans, but the polymorphisms may be implicated in different susceptibilities for
lung cancer
across different populations because of underlying genetic heterogeneity. We therefore conducted a study to examine this relationship in non-smoking Chinese. As a result , no significant associations were observed between SNPs and NSCLCs, whetehr of squamous cell or adenocarcinoma type. Results indicated polymorphisms of IL-7R, IL-13 and IL-15 are not major contributors to NSCLC susceptibility, although we can not rule out synergistic effects with cigarette smoke in NSCLC development in smoking Chinese.
Asian
Pac
J Cancer Prev 2011
PMID:Lack of associations of polymorphisms of IL-7R, IL-13 and IL-15 with NSCLCs in non-smoking Chinese. 2247 60
To identify a cisplatin resistance predictor to reduce or prevent unnecessary side effects, we firstly established four cisplatin-resistant sub-lines and compared their protein profiles with cisplatin-sensitive parent
lung cancer
cell lines using two-dimensional gel electrophoresis. Between the cisplatin-resistant and -sensitive cells, a total of 359 protein spots were differently expressed (>1.5 fold), and 217 proteins (83.0%) were identified. We focused on a mitochondrial protein, hydroxyl-coenzyme A dehydrogenase/3-ketoacyl-coenzyme A thiolase/enoyl-coenzyme A hydratase alpha subunit (HADHA), which was increased in all cisplatin-resistant cells. Furthermore, pre- treated biopsy specimens taken from patients who showed resistance to platinum-based treatment showed a significantly higher positive rate for HADHA in all cases (p=0.00367), including non-small cell lung carcinomas (p=0.002), small-cell lung carcinomas (p=0.038), and adenocarcinomas (p=0.008). These results suggest that the expression of HADHA may be a useful marker to predict resistance to platinum-based chemotherapy in patients with
lung cancer
.
Asian
Pac
J Cancer Prev 2011
PMID:HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer. 2247 97
This paper presents the most recent data on cancer rates and the burden of cancer in the ASEAN region. Epidemiological data were sourced from GLOBOCAN 2008 and disability adjusted life years (DALYs) lost were estimated using the standard methodology developed within the World Health Organization's Global Burden of Disease study. Overall, it was estimated there were over 700,000 new cases of cancer and 500,000 cancer deaths in ASEAN in the year 2008, leading to approximately 7.5 million DALYs lost in one year. The most commonly diagnosed cancers were lung (98,143), breast (86,842) and liver cancers (74,777). The most common causes of cancer death were
lung cancer
(85,772), liver cancer (69,115) and colorectal cancer (44,280). The burden of cancer in terms of DALYs lost was highest in Laos, Viet Nam and Myanmar and lowest in Brunei, Singapore and the Philippines. Significant differences in the patterns of cancer from country to country were observed. Another key finding was the major impact played by population age distribution on cancer incidence and mortality. Cancer rates in ASEAN are expected to increase with ageing of populations and changes in lifestyles associated with economic development. Therefore, ASEAN member countries are strongly encouraged to put in place cancer-control health care policies, focussed on strengthening the health systems to cope with projected increases in cancer prevention, treatment and management needs.
Asian
Pac
J Cancer Prev 2012
PMID:The burden of cancer in member countries of the Association of Southeast Asian Nations (ASEAN). 2252 99
Video-assisted thoracic surgery (VATS) has been recommended as more optimal surgical technique than traditional thoracotomy for lobectomy in
lung cancer
, but it is not well defined. Here, we compared VATS and traditional thoracotomy based on clinical data. From November 2008 to November 2010, 180 patients underwent lobectomy for non-small-cell
lung cancer
(NSCL) identified by computerized tomography. Of them, 83 cases were performed with VATS and 97 by thoracotomy. Clinical parameters, consisting of blood loss, operating time, number of lymph node dissection, days of pleural cavity drainage, and length of stay were recorded and evaluated with t test. No significant difference was observed between the VATS and thoracotomy groups in the average intraoperative blood loss, number of lymph node dissections, and days of pleural cavity drainage. While the average operating time in the VATS group was significantly longer than that in thoracotomy group, recurrence was only present in one case, as opposed to 7 cases in the thoracotomy group In conclusion, similar therapeutic effects were demonstrated in VATS and thoracotomy for NSCL. However, VATS lobectomy was associated with fewer complications, recurrence and shorter length of stay.
Asian
Pac
J Cancer Prev 2012
PMID:Video-assisted thoracic surgery versus thoracotomy for non-small-cell lung cancer. 2252 4
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>